Mike Buck

VDyne Inc., a privately held medical device company developing a transcatheter tricuspid valve replacement (TTVR) system for the treatment of tricuspid regurgitation, has appointed Mike Buck as Chairman and Chief Executive Officer.

Mr. Buck brings over three decades of leadership experience in the cardiovascular medical technology sector. He most recently served as Chief Executive Officer of Verge Medical and previously founded and led TRUVIC Medical, which was later acquired by Imperative Care.
 
Earlier in his career, he held key leadership roles at Cardinal Health, where he served as President of the Medical Products Division, and at Abbott, where he was Corporate Vice President and global commercial leader for its Vascular business. He also led Abbott’s global Licensing and Acquisitions function, contributing to strategic growth initiatives.

VDyne continues to make significant progress in advancing its TTVR technology. The company has conducted clinical studies across 15 countries and has successfully completed more than 100 TTVR procedures to date. It has also received the FDA’s Breakthrough Device designation, underscoring the potential of its technology to address unmet clinical needs.

With plans to pursue CE Mark approval and initiate its U.S. pivotal clinical study, VDyne is positioning itself at the forefront of next-generation therapies for tricuspid regurgitation. Mr. Buck’s appointment is expected to further accelerate the company’s clinical and commercial development efforts